KRAS G12C Inhibition in Advanced NSCLC: AMG 510

preview_player
Показать описание
Implications for treating patients with advanced non–small cell lung cancer who harbor a KRAS G12C mutation with AMG 510 based on data demonstrated by the CodeBreak 100 study.

  1. OncLive
  2. cancer
  3. oncology
Рекомендации по теме
KRAS G12C Inhibition 0:07:51

KRAS G12C Inhibition in Advanced NSCLC: AMG 510

KRAS G12C Inhibition 0:02:53

KRAS G12C Inhibition in Advanced NSCLC: MRTX849

KRAS G12C Inhibition 0:02:20

KRAS G12C Inhibition in Advanced NSCLC: MRTX849

KRAS G12C Inhibition 0:04:09

KRAS G12C Inhibition in Advanced NSCLC: AMG 510

Molecular determinants of 0:01:59

Molecular determinants of KRAS G12C inhibitor efficacy in advanced NSCLC

ESMO highlights: KRAS 0:02:09

ESMO highlights: KRAS G12C inhibitors

Safety of sotorasib 0:07:19

Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal cancer

KRAS G12C Inhibitors: 0:05:23

KRAS G12C Inhibitors: Acquired Resistance and Combo Strategies

Development of KRAS 0:05:29

Development of KRAS G12C-Targeted Therapy in NSCLC

KRAS G12C inhibitors 0:00:58

KRAS G12C inhibitors for GI cancer

Sotorasib achieved clinically 0:02:29

Sotorasib achieved clinically meaningful activity in KRAS G12C-mutated advanced pancreatic cancer

Mechanism of action 0:00:31

Mechanism of action of the novel KRASG12C inhibitor GDC-6036

Mechanisms of acquired 0:04:29

Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

Dr Akhil Kapoor 0:05:07

Dr Akhil Kapoor | KRASG12C Inhibition with Sotorasib in Advanced Solid Tumours

Phase II CodeBreak 0:03:01

Phase II CodeBreak 100 trial of sotorasib in advanced NSCLC

CodeBreaK 200: sotorasib 0:02:42

CodeBreaK 200: sotorasib versus docetaxel in pretreated KRAS G12C-mutant NSCLC

LY3537982: a novel 0:01:19

LY3537982: a novel KRAS G12C inhibitor in solid tumors

Mechanisms of resistance 0:03:17

Mechanisms of resistance to KRAS G12C inhibitors

What the New 0:10:45

What the New KRAS Inhibitor Means for Lung Cancer - Medpage Today

Advances in the 0:01:27

Advances in the development of KRAS inhibitors

Challenges in targeting 0:01:09

Challenges in targeting KRASG12C mutations

Real-world outcomes by 0:05:14

Real-world outcomes by co-mutation status in KRAS G12C-mutant NSCLC

Sotorasib: first targeted 0:00:57

Sotorasib: first targeted approval for KRAS G12C mutated NSCLC

Overcoming resistance to 0:01:12

Overcoming resistance to KRAS G12C inhibitors in NSCLC